Oncology Venture   Report issue

For profit Phase 2
Founded: Horsholm Denmark (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2013
NCT01861496
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Oncology Venture

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: Oncology Venture (4) Acquired (1)

2x-121 (2 trials)

apo010 (1 trial)

cisplatin (platinol) (1 trial)

irofulven (1 trial)

prednisolone (hydeltra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5